Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13025755 | 0.87 | HCRTR1 (0.33) | — | |
| SCHEMBL12834385 | 0.85 | HCRTR1 (0.34) | — | |
| SCHEMBL13067296 | 0.85 | FFAR4 (0.30) | FFAR4 | |
| SCHEMBL13025929 | 0.83 | S1PR1 (0.32) | S1PR1S1PR3 | |
| SCHEMBL13025769 | 0.83 | HCRTR1 (0.33) | FFAR4S1PR1S1PR3 | |
| SCHEMBL13025853 | 0.83 | FFAR1 (0.34) | FFAR1FFAR4MAPT | |
| SCHEMBL13025777 | 0.83 | FFAR1 (0.39) | FFAR1FFAR4MAPTTHRBRAB9A | |
| SCHEMBL14362959 | 0.80 | GABRA1 (0.36) | FFAR1FFAR4S1PR1S1PR3ALDH1A1 | |
| SCHEMBL13025918 | 0.79 | ACACB (0.31) | — | |
| SCHEMBL13025979 | 0.79 | MAPT (0.34) | FFAR1FFAR4MAPTTHRBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | FFAR1 2982/4885FFAR4 3309/4885MAPT 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.